Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China

被引：0

作者：

Mu, Lifeng ^{[1
]}

Zhou, Benhong ^{[1
]}

机构：

[1] Wuhan Univ, Dept Pharm, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China

来源：

ADVANCES IN THERAPY | 2020年 / 37卷 / 02期

关键词：

Alectinib; China; Cost-effectiveness; Non-small-cell lung cancer; Oncology; Survival extrapolation;

D O I：

10.1007/s12325-019-01204-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：968 / 970

页数：3

共 6 条

[1]

Baio G, 2016, SAGE J, DOI [10.5301/grhta.5000247, DOI 10.5301/GRHTA.5000247]

[2] Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach [J].

Cooper, NJ ;

Sutton, AJ ;

Abrams, KR ;

Turner, D ;

Wailoo, A .

HEALTH ECONOMICS, 2004, 13 (03) :203-226

[3] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis [J].

Fan, Junsheng ;

Fong, Tszhei ;

Xia, Zengfei ;

Zhang, Jian ;

Luo, Peng .

CANCER MEDICINE, 2018, 7 (10) :4993-5005

[4] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China [J].

Guan, Haijing ;

Sheng, Yanan ;

Guo, Wanjie ;

Han, Sheng ;

Shi, Luwen .

ADVANCES IN THERAPY, 2019, 36 (05) :1114-1125

[5] Extrapolation of Survival Curves from Cancer Trials Using External Information [J].

Guyot, Patricia ;

Ades, Anthony E. ;

Beasley, Matthew ;

Lueza, Beranger ;

Pignon, Jean-Pierre ;

Welton, Nicky J. .

MEDICAL DECISION MAKING, 2017, 37 (04) :353-366

[6]

Mok TSK, 2017, ANN ONCOL, DOI [10.1093/annonc/mdx729.009, DOI 10.1093/ANNONC/MDX729.009]

← 1 →